ClinicalTrials.gg
CompletedNCT00722371Updated May 12, 2017Results posted

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

A Phase 3 interventional study of Sitagliptin phosphate and Pioglitazone hydrochloride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,615
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
3rd of 197
1,615 · median 102
Started
2008
with 22 others
Phase 3
74 of 198
none open now
Registered
49th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 49th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is highly unlikely to conceive
  • Patient meets one of the 3 categories is naïve to all antihyperglycemic agent (AHA) therapies, or is non-naïve based upon the patient's current diet, medical regimen and screening A1c patient is currently not on AHA with a screening A1c >=7.5 % and =\<11.0 % patient is currently on either metformin pr sulfonylurea monotherapy with a screening A1c >=7.0 % and =\<9.0 %

Exclusion criteria

Exclusion Criteria

  • Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has C=peptide value of =\<0.8 ng/mL
  • Patient has previously been treated with insulin, thiazolidinedione (TZD) (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a clinical study with any DPP-4 inhibitor or incretin mimetic
  • Patient is on a weight loss program and is not in the maintenance phase or has started a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks
  • Patient has undergone surgery within the prior 30 days or has major surgery planned during the study
  • Patient has a medical history of active liver disease including chronic active or C or symptomatic gallbladder disease including primary biliary cirrhosis
  • Patient has received treatment with an product within 12 weeks prior to Visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,615 participants (actual)

Study arms

  • Experimental
    Sitagliptin 100 mg

    Drug: Sitagliptin phosphate · Drug: Matching placebo to pioglitazone · Drug: Metformin

  • Experimental
    Pioglitazone 15 mg

    Drug: Pioglitazone hydrochloride · Drug: Matching placebo to sitagliptin · Drug: Metformin

  • Experimental
    Pioglitazone 30 mg

    Drug: Pioglitazone hydrochloride · Drug: Matching placebo to sitagliptin · Drug: Metformin

  • Experimental
    Pioglitazone 45 mg

    Drug: Pioglitazone hydrochloride · Drug: Matching placebo to sitagliptin · Drug: Metformin

  • Experimental
    Sitagliptin 100 mg/ Pioglitazone 15 mg

    Drug: Sitagliptin phosphate · Drug: Pioglitazone hydrochloride · Drug: Metformin

  • Experimental
    Sitagliptin 100 mg/ Pioglitazone 30 mg

    Drug: Sitagliptin phosphate · Drug: Pioglitazone hydrochloride · Drug: Metformin

  • Experimental
    Sitagliptin 100 mg/ Pioglitazone 45 mg

    Drug: Sitagliptin phosphate · Drug: Pioglitazone hydrochloride · Drug: Metformin

Interventions

  • Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.

    Also known as: Januvia, Tesavel, Xelevia, Ristaben

  • Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.

    Also known as: Actos

  • DrugMatching placebo to sitagliptin

    Matching placebo to sitagliptin orally once daily for 54 weeks.

  • DrugMatching placebo to pioglitazone

    Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.

  • Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (A1C) at Week 24

    A1C represents the percentage of glycosylated hemoglobin.

    Time frame: Baseline and Week 24

  2. Change From Baseline in A1C at Week 54

    A1C represents the percentage of glycosylated hemoglobin.

    Time frame: Baseline and Week 54

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Time frame: Baseline and Week 24

  2. Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24

    PMG was measured using the Meal Tolerance Test (MTT).

    Time frame: Baseline and Week 24

  3. Change From Baseline in FPG at Week 54

    Time frame: Baseline and Week 54

  4. Change From Baseline in 2-Hour PMG at Week 54

    PMG was measured using the Meal Tolerance Test (MTT).

    Time frame: Baseline and Week 54

07

Results

Posted Oct 17, 2011

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Started231230233230230231230
Completed175158168167182178179
Not completed56726563485351
Withdrew: Adverse event613910684
Withdrew: Contraindication0010000
Withdrew: Creatinine / creatinine clearance2123211
Withdrew: Excluded medication0110001
Withdrew: Hyperglycemia2642511
Withdrew: Hypoglycemia1000000
Withdrew: Lack of efficacy4666230
Withdrew: Lost to follow-up1114211381613
Withdrew: Physician decision5225234
Withdrew: Pregnancy1100010
Withdrew: Protocol violation6101421
Withdrew: Withdrawal by subject18271923191826

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 24

A1C represents the percentage of glycosylated hemoglobin.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1C (A1C) at Week 24
Percentage of glycosylated hemoglobinSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Change From Baseline in Hemoglobin A1C (A1C) at Week 24-1.09 (-1.29 to -0.89)-0.88 (-1.09 to -0.68)-1.21 (-1.41 to -1.02)-1.20 (-1.40 to -1.00)-1.53 (-1.73 to -1.34)-1.63 (-1.82 to -1.43)-1.81 (-2.00 to -1.62)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/dLSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-24.3 (-32.0 to -16.5)-19.5 (-27.2 to -11.7)-29.9 (-37.6 to -22.3)-37.4 (-45.1 to -29.7)-41.0 (-48.5 to -33.5)-46.9 (-54.6 to -39.3)-52.0 (-59.6 to -44.5)
SecondaryChange From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24

PMG was measured using the Meal Tolerance Test (MTT).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24
mg/dLSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24-51.1 (-64.0 to -38.2)-30.6 (-44.0 to -17.3)-52.5 (-64.9 to -40.2)-66.6 (-79.8 to -53.5)-69.2 (-81.7 to -56.7)-85.5 (-98.4 to -72.6)-93.8 (-106.4 to -81.2)
PrimaryChange From Baseline in A1C at Week 54

A1C represents the percentage of glycosylated hemoglobin.

Time frame:
Baseline and Week 54
Reported as:
Least squares mean · Percent of glycosylated hemoglobin
Change From Baseline in A1C at Week 54
Percent of glycosylated hemoglobinSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Change From Baseline in A1C at Week 54-0.93 (-1.15 to -0.72)-0.74 (-0.96 to -0.53)-1.16 (-1.37 to -0.95)-1.23 (-1.45 to -1.02)-1.45 (-1.65 to -1.24)-1.49 (-1.71 to -1.28)-1.78 (-1.99 to -1.58)
SecondaryChange From Baseline in FPG at Week 54
Time frame:
Baseline and Week 54
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 54
mg/dLSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Change From Baseline in FPG at Week 54-13.1 (-21.6 to -4.5)-10.5 (-19.0 to -2.0)-24.0 (-32.4 to -15.5)-33.3 (-41.8 to -24.8)-33.9 (-42.2 to -25.7)-37.1 (-45.5 to -28.6)-47.8 (-56.1 to -39.5)
SecondaryChange From Baseline in 2-Hour PMG at Week 54

PMG was measured using the Meal Tolerance Test (MTT).

Time frame:
Baseline and Week 54
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-Hour PMG at Week 54
mg/dLSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Change From Baseline in 2-Hour PMG at Week 54-37.0 (-50.2 to -23.7)-26.7 (-40.5 to -13.0)-46.8 (-59.6 to -34.1)-58.2 (-71.6 to -44.7)-64.7 (-77.6 to -51.8)-69.7 (-83.1 to -56.4)-88.2 (-101.2 to -75.3)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg—14/231 (6.1%)60/231 (26%)
Pioglitazone 15 mg—10/230 (4.3%)41/230 (17.8%)
Pioglitazone 30 mg—5/233 (2.1%)45/233 (19.3%)
Pioglitazone 45 mg—11/230 (4.8%)55/230 (23.9%)
Sitagliptin 100 mg/ Pioglitazone 15 mg—12/230 (5.2%)48/230 (20.9%)
Sitagliptin 100 mg/ Pioglitazone 30 mg—15/231 (6.5%)56/231 (24.2%)
Sitagliptin 100 mg/ Pioglitazone 45 mg—7/230 (3%)46/230 (20%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
Atrial fibrillationCardiac disorders0/2310/2300/2330/2300/2302/2310/230
Coronary artery diseaseCardiac disorders2/2310/2300/2330/2301/2300/2310/230
Myocardial infarctionCardiac disorders0/2310/2300/2330/2301/2302/2310/230
ArteriosclerosisVascular disorders2/2310/2300/2330/2300/2300/2310/230
Atrial flutterCardiac disorders0/2310/2300/2330/2300/2300/2311/230
Cardiac failure congestiveCardiac disorders0/2310/2300/2330/2300/2300/2311/230
Mitral valve diseaseCardiac disorders0/2310/2300/2330/2300/2300/2311/230
Myocardial ischaemiaCardiac disorders1/2310/2300/2330/2301/2300/2310/230
Optic ischaemic neuropathyEye disorders0/2310/2300/2331/2300/2300/2310/230
Anal fissureGastrointestinal disorders0/2310/2300/2330/2300/2300/2311/230
Most frequent other events
Most frequent other events
EventSitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mg
HypoglycaemiaMetabolism and nutrition disorders25/23120/23022/23320/23020/23026/23124/230
HeadacheNervous system disorders17/2316/2309/23311/2308/23014/2315/230
NasopharyngitisInfections and infestations13/23110/23012/2339/23012/23015/2318/230
HypertensionVascular disorders7/2315/2304/23310/23013/2306/2310/230
Upper respiratory tract infectionInfections and infestations10/2316/2308/23312/23011/2309/23111/230

Baseline characteristics

Age, Customized
Age, Customized(Participants)Sitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mgTotal
<=20 years00000000
21 to 30 years562558435
31 to 40 years37393320173415195
41 to 50 years64736070736068468
51 to 60 years83678876807587556
61 to 70 years31344553444951307
>70 years111156115554
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mgPioglitazone 15 mgPioglitazone 30 mgPioglitazone 45 mgSitagliptin 100 mg/ Pioglitazone 15 mgSitagliptin 100 mg/ Pioglitazone 30 mgSitagliptin 100 mg/ Pioglitazone 45 mgTotal
Female95821061171129695703
Male136148127113118135135912
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Henry RR, Staels B, Fonseca VA, Chou MZ, Teng R, Golm GT, Langdon RB, Kaufman KD, Steinberg H, Goldstein BJ. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. Diabetes Obes Metab. 2014 Mar;16(3):223-30. doi: 10.1111/dom.12194. Epub 2013 Aug 29. PubMed 23909985 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Oct 2010, 25 months.

Results were first posted in Oct 2011, 11 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2008
First posted
Jul 25, 2008
StartActual
Sep 5, 2008
Primary completionActual
Oct 26, 2010
CompletionActual
Mar 25, 2011
Results first posted
Oct 17, 2011
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00722371
Responsible party
Sponsor
First posted
Jul 25, 2008
Start date
Sep 5, 2008
Primary completion
Oct 26, 2010
Completion
Mar 25, 2011
Results posted
Oct 17, 2011
Last update
May 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Pioglitazone

Start the discussion